MS Drug Candidate May Also Treat Ulcerative Colitis

MS Drug Candidate May Also Treat Ulcerative Colitis
Receptos, Inc., a San Diego-based biotechnology company, announced promising new clinical data for its drug candidate RPC1063 for ulcerative colitis. The drug was first discovered and synthesized at The Scripps Research Institute (TSRI) by the research groups of Professor Hugh Rosen and Professor Ed Roberts. Ulcerative colitis (UC) is a key form of inflammatory bowel disease (IBD), characterized by chronic inflammation

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *